Clinical trial registry record

A Study of Avastin (Bevacizumab) in Combination With Gemcitabine With or Without Cisplatin in First-Line Treatment of Elderly Patients With Non-Small Cell Lung Cancer

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated October 8, 2015.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT01077713
Last registry update
October 8, 2015
Status
Completed
Phase
Phase 2
Sponsor
Hoffmann-La Roche
Enrollment
86
Countries
Italy
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 2
Study design
RANDOMIZED · PARALLEL · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
86
Population
ALL · 70 Years
Duration
2010-02-01 to 2014-07-01
Intervention
bevacizumab [Avastin]; cisplatin; gemcitabine
Comparator
Not reported
Outcomes measured
Percentage of Participants Alive and Without Progressive Disease at Month 6 — Month 6; Percentage of Participants With Disease Progression or Death — Baseline; Day 15 of Cycles 3 and 6; Month 6 and then eve…; Progression Free Survival (PFS) — Baseline; Day 15 of Cycles 3 and 6; Month 6 and then every 3 months until disease pro…; Percentage of Participants Alive at 12 Months After Randomization — 1 year; Percentage of Participants Who Died — From randomization to death or end of the study (up to 53 months); Overall Survival (OS) — From randomization to death or end of the study (up to 53 months); Percentage of Participants by Best Overall Response — Baseline; Day 15 of Cycles 3 and 6; Month 6 and then every 3 mont…; Percentage of Participants With an Objective Response — Cycle 3 Day 15, Cycle 6 Day 15 and at Month 6; Percentage of Participants With Disease Control — Cycle 3 Day 15, Cycle 6 Day 15 and at Month 6; Duration of Response (DoR) — Baseline; Day 15 of Cycles 3 and 6; Month 6 and then every 3 months until disease progress…
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Cancer and ageing · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Source terminology contains a controlled topic term. Title supplies ageing or longevity context.

Automated source check 100% · update recency 35%. These figures help sort records; they are not medical ratings.

cancer and aging
Read the original source →Export JSON